Soligenix Inc. (SNGX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Soligenix Inc. stock (SNGX) is currently trading at $1.20. Soligenix Inc. PS ratio (Price-to-Sales) is 3874.85. Analyst consensus price target for SNGX is $17.50. WallStSmart rates SNGX as Sell.
- SNGX PE ratio analysis and historical PE chart
- SNGX PS ratio (Price-to-Sales) history and trend
- SNGX intrinsic value — DCF, Graham Number, EPV models
- SNGX stock price prediction 2025 2026 2027 2028 2029 2030
- SNGX fair value vs current price
- SNGX insider transactions and insider buying
- Is SNGX undervalued or overvalued?
- Soligenix Inc. financial analysis — revenue, earnings, cash flow
- SNGX Piotroski F-Score and Altman Z-Score
- SNGX analyst price target and Smart Rating
Soligenix Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Soligenix Inc. (SNGX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Soligenix Inc. (SNGX) Key Strengths (1)
Trading at 1.58x book value, attractively priced
Supporting Valuation Data
Soligenix Inc. (SNGX) Areas to Watch (6)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 3874.8x annual revenue
Very low institutional interest at 9.69%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Soligenix Inc. (SNGX) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.58) suggest the stock is attractively priced.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Revenue Growth. Some valuation metrics including PEG Ratio (N/A), Price/Sales (3874.85) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -165.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -165.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SNGX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SNGX's Price-to-Sales ratio of 3874.85x trades 1958% above its historical average of 188.32x (96th percentile), historically expensive. The current valuation is 0% below its historical high of 3874.85x set in Mar 2026, and 1076247% above its historical low of 0.36x in Jun 2012. Over the past 12 months, the PS ratio has expanded from ~186.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Soligenix Inc. (SNGX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Soligenix Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.03, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Soligenix Inc..
Bottom Line
Soligenix Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Soligenix Inc.(SNGX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. The company is headquartered in Princeton, New Jersey.